Bimal Shah

Direttore/Membro del Consiglio presso ANEBULO PHARMACEUTICALS, INC.

48 anni

Health Technology

Consumer Services

Relazioni attive

Nome	Sesso	Età	Società collegate	Collaborazione
Rajesh Shrotriya	M	79	SPECTRUM PHARMACEUTICALS, INC. Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	24 anni
Joseph Lawler	M	52	ANEBULO PHARMACEUTICALS, INC.	4 anni
Abraham Noah Oler	M	48	SPECTRUM PHARMACEUTICALS, INC. Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	14 anni
Luigi Lenaz	M	83	SPECTRUM PHARMACEUTICALS, INC. Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	14 anni
Daniel George	M	54	ANEBULO PHARMACEUTICALS, INC.	1 anni
Nora Brennan	F	55	SPECTRUM PHARMACEUTICALS, INC.	4 anni
Jeffrey R. Latts	M	76	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	17 anni
Karah Parschauer	F	46	ANEBULO PHARMACEUTICALS, INC.	3 anni
Areta Kupchyk	F	67	ANEBULO PHARMACEUTICALS, INC.	3 anni
Aron English	M	41	ANEBULO PHARMACEUTICALS, INC.	4 anni
Keith M. McGahan	M	-	SPECTRUM PHARMACEUTICALS, INC.	8 anni
Scott Anderson	M	-	ANEBULO PHARMACEUTICALS, INC.	2 anni
Nathaniel Calloway	M	42	ANEBULO PHARMACEUTICALS, INC.	2 anni
Richard Cunningham	M	54	ANEBULO PHARMACEUTICALS, INC.	1 anni
James E. Shields	M	72	SPECTRUM PHARMACEUTICALS, INC. Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	14 anni
Kenneth Lin	M	51	ANEBULO PHARMACEUTICALS, INC.	3 anni
Jason Aryeh	M	55	ANEBULO PHARMACEUTICALS, INC.	3 anni
Madison Damour	F	-	ANEBULO PHARMACEUTICALS, INC.	-
Michael A. Grabow	M	-	SPECTRUM PHARMACEUTICALS, INC.	11 anni
Michael E. Schick	M	57	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	15 anni
Kenneth Cundy	M	65	ANEBULO PHARMACEUTICALS, INC.	2 anni

Mostra altro

Grafico relazionale

Relazione in diverse aziende

Relazioni precedenti

Nome	Sesso	Età	Società collegate	Collaborazione
Joseph W. Turgeon	M	66	SPECTRUM PHARMACEUTICALS, INC.	9 anni
Thomas Riga	M	48	SPECTRUM PHARMACEUTICALS, INC.	10 anni
Paul Berns	M	57	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	6 anni
Kurt Gustafson	M	55	SPECTRUM PHARMACEUTICALS, INC.	9 anni
Elly Ryu	F	43	SPECTRUM PHARMACEUTICALS, INC.	10 anni
Brett Scott	M	73	SPECTRUM PHARMACEUTICALS, INC.	-
Dolatrai Vyas	M	80	SPECTRUM PHARMACEUTICALS, INC.	9 anni
Krishan K. Arora	M	83	SPECTRUM PHARMACEUTICALS, INC.	3 anni
William Ashton	M	73	SPECTRUM PHARMACEUTICALS, INC.	5 anni
Cecilia Gonzalo	F	49	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	1 anni
Simon Allen	M	56	ANEBULO PHARMACEUTICALS, INC.	1 anni
Jeffrey Vacirca	M	55	SPECTRUM PHARMACEUTICALS, INC.	5 anni
Anthony Maida	M	59	SPECTRUM PHARMACEUTICALS, INC.	16 anni
Elizabeth Czerepak	F	58	SPECTRUM PHARMACEUTICALS, INC.	1 anni
Robert Fralin	M	-	SPECTRUM PHARMACEUTICALS, INC.	-
Bernice Welles	M	71	SPECTRUM PHARMACEUTICALS, INC.	-
Gilles Gagnon	M	70	SPECTRUM PHARMACEUTICALS, INC.	-
Marc H. Graboyes	M	54	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	8 anni
Raymond Cohen	M	65	SPECTRUM PHARMACEUTICALS, INC.	7 anni
David Stout	M	70	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	3 anni
Anton G. Gueth	M	67	SPECTRUM PHARMACEUTICALS, INC.	1 anni
Jonathan Leff	M	55	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	7 anni
Ricardo J. Gonzalez	M	53	SPECTRUM PHARMACEUTICALS, INC.	6 anni
David Clark	M	56	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	8 anni
Leonard M. Greenstein	M	48	SPECTRUM PHARMACEUTICALS, INC.	7 anni
Antonis Koutsoukos	M	-	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	6 anni
Francois Lebel	M	72	SPECTRUM PHARMACEUTICALS, INC.	4 anni
Jennifer Carver	F	70	SPECTRUM PHARMACEUTICALS, INC.	2 anni
Stephanie Vigue	F	-	SPECTRUM PHARMACEUTICALS, INC.	3 anni
Dennis Kim	M	55	SPECTRUM PHARMACEUTICALS, INC.	1 anni
Lyndah K. Dreiling	M	-	SPECTRUM PHARMACEUTICALS, INC.	-
Lisa A. Croissant	F	-	SPECTRUM PHARMACEUTICALS, INC.	-
Al DeJesus	M	-	SPECTRUM PHARMACEUTICALS, INC.	-
Dilip J. Mehta	M	91	SPECTRUM PHARMACEUTICALS, INC.	2 anni
Pramod Gupta	M	63	SPECTRUM PHARMACEUTICALS, INC.	7 anni
Brian Holzer	M	-	SPECTRUM PHARMACEUTICALS, INC.	-
Nozar Azarnia	M	-	SPECTRUM PHARMACEUTICALS, INC.	-
Steven Fruchtman	M	73	SPECTRUM PHARMACEUTICALS, INC.	2 anni
Bruce Goldsmith	M	58	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	4 anni
Charles Q. Morris	M	59	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	2 anni
George Uy	M	67	SPECTRUM PHARMACEUTICALS, INC.	4 anni
Bruce K. Bennett	M	73	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	4 anni
Seth Fischer	M	68	SPECTRUM PHARMACEUTICALS, INC.	3 anni
George Tidmarsh	M	64	SPECTRUM PHARMACEUTICALS, INC.	1 anni
Michael A. Adam	M	66	SPECTRUM PHARMACEUTICALS, INC.	2 anni
Kenneth Joseph Keller	M	61	SPECTRUM PHARMACEUTICALS, INC.	2 anni
Lee F. Allen	M	72	SPECTRUM PHARMACEUTICALS, INC.	3 anni
Luke Seikkula	M	60	SPECTRUM PHARMACEUTICALS, INC.	3 anni
Denny Chu	M	-	SPECTRUM PHARMACEUTICALS, INC.	6 anni

Statistiche

Paese	Relazioni	% del totale
Stati Uniti	70	100.00%

Età delle relazioni

Attive

Scorse

Uomo

Donna

Amministratori

Dirigenti

Provenienza delle relazioni

Borsa valori
Insiders
Bimal Shah
Contatti personali